DPP-4 inhibitors and COVID-19 outcomes

The French CORONADO study provides reassuring data about the safety of dipeptidyl peptidase-4 inhibitors in the context of the pandemic, and suggests that prescribing practice need not be changed.

Click here to read our summary.

Share this article

News from the American Diabetes Association’s Scientific Sessions

Tirzepatide reduces body weight by up to 22.5% in participants with overweight or obesity

UK Kidney Association releases guideline on SGLT2 inhibitor use

EMPEROR-Preserved: Empagliflozin first therapeutic agent to demonstrate benefits in people with HFpEF

Dapagliflozin approved in the EU for treatment of CKD in people with and without type 2 diabetes

Diabetes before, during and after pregnancy

Early-onset and youth-onset type 2 diabetes: new factsheet

News from the American Diabetes Association’s Scientific Sessions

Headlines from the recent ADA conference in New Orleans.

13 Jun 2022

Tirzepatide reduces body weight by up to 22.5% in participants with overweight or obesity

Top-line results from the SURMOUNT-1 clinical trial.

5 May 2022

UK Kidney Association releases guideline on SGLT2 inhibitor use

The UK Kidney Association has released its Clinical Practice Guideline on SGLT2 inhibitor use in adults with kidney disease.

19 Oct 2021

For the latest news and articles

Resources

Journals

Useful information